Physician profile
Travis Bowles
NPI 1912094046
$1,876.25
in general payments reported to CMS, 2019-2025
20 companies · $446 in 2025
The $446 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.42 · 2020: $75.39 · 2021: $154 · 2022: $300 · 2023: $377 · 2024: $438 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $427.20 | 2021-2025 | Vraylar, Synthroid |
| Glaxosmithkline, LLC. | $202.86 | 2022-2025 | Shingrix, Arexvy, Flulaval Quadrivalent |
| Abbott Laboratories | $158.30 | 2020-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $113.16 | 2020-2025 | Veozah |
| Pfizer INC. | $97.87 | 2019-2024 | |
| Dexcom, INC. | $89.34 | 2022-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $48.99 | 2024-2025 | Heplisav-B |
| Currax Pharmaceuticals LLC | $44.00 | 2019-2020 | |
| Boston Scientific Corporation | $42.29 | 2025 | General - Pain Management |
| Lilly USA, LLC | $42.00 | 2022-2024 | Mounjaro |
| Amgen INC. | $36.45 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $25.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.82 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.03 | 2024 | |
| Biogen, INC. | $16.71 | 2025 | Leqembi |
| Allergan, INC. | $13.80 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.98 | 2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.